Joseph Monahan - Feb 9, 2022 Form 4 Insider Report for Aclaris Therapeutics, Inc. (ACRS)

Role
Chief Scientific Officer
Signature
/s/ Mark Ballantyne, Attorney-in-Fact
Stock symbol
ACRS
Transactions as of
Feb 9, 2022
Transactions value $
-$4,857
Form type
4
Date filed
2/11/2022, 03:22 PM
Previous filing
Feb 3, 2022
Next filing
Mar 3, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ACRS Common Stock Sale -$4.86K -383 -0.44% $12.68 87.3K Feb 9, 2022 Direct F1
holding ACRS Common Stock 193 Feb 9, 2022 By Spouse
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares sold to satisfy withholding tax obligations upon the delivery of shares of common stock for restricted stock units that vested on February 1, 2022 pursuant to preexisting sell-to-cover elections.